Marisa C Weiss1,2,3,4, Julianne E Hibbs5, Meghan E Buckley6, Sherry R Danese7, Adam Leitenberger1, Melissa Bollmann-Jenkins1, Sam W Meske4,6, Katherine E Aliano-Ruiz4, Theresa W McHugh5, Sharon L Larson6, Elaine H Le8, Nancye L Green9, Paul B Gilman4, Virginia G Kaklamani10, Rowan T Chlebowski11, Diana M Martinez12. 1. Breastcancer.org, Ardmore, Pennsylvania. 2. Socanna, Narberth, Pennsylvania. 3. Radiation Oncology, Lankenau Medical Center, Wynnewood, Pennsylvania. 4. Lankenau Institute for Medical Research, Wynnewood, Pennsylvania. 5. Medical Oncology, Lankenau Medical Center, Wynnewood, Pennsylvania. 6. Center for Population Health Research, Main Line Health, Wynnewood, Pennsylvania. 7. Outcomes Insights, Agoura Hills, California. 8. Healthline, San Francisco, California. 9. Donovan/Green, New York, New York. 10. Medical Oncology, Internal Medicine, University of Texas Health San Antonio, San Antonio, Texas. 11. Lundquist Institute for Biomedical Innovation, Harbor-UCLA Medical Center, Torrance, California. 12. Department of Psychiatry, Columbia University Irving Medical Center, New York, New York.
Abstract
BACKGROUND: The goal of this study was to characterize cannabis use among patients with breast cancer, including their reasons for and timing of use, their sources of cannabis information and products, their satisfaction with the information found, their perceptions of its safety, and their dialogue about cannabis with their physicians. METHODS: United States-based members of the Breastcancer.org and Healthline.com communities with a self-reported diagnosis of breast cancer within 5 years (age ≥ 18 years) were invited to participate in an anonymous online survey. After informed consent was obtained, nonidentifiable data were collected and analyzed. RESULTS: Of all participants (n = 612), 42% (n = 257) reported using cannabis for relief of symptoms, which included pain (78%), insomnia (70%), anxiety (57%), stress (51%), and nausea/vomiting (46%). Furthermore, 49% of cannabis users believed that medical cannabis could be used to treat cancer itself. Of those taking cannabis, 79% had used it during treatment, which included systemic therapies, radiation, and surgery. At the same time, few (39%) had discussed it with any of their physicians. CONCLUSIONS: A significant percentage of survey participants (42%) used cannabis to address symptoms; approximately half of these participants believed that cannabis could treat cancer itself. Most participants used cannabis during active cancer treatment despite the potential for an adverse event during this vulnerable time. Furthermore, most participants believed that cannabis was safe and were unaware that product quality varied widely and depended on the source. This study reviews the research on medicinal cannabis in the setting of these findings to help physicians to recognize its risks and benefits for patients with cancer. LAY SUMMARY: Almost half of patients with breast cancer use cannabis, most commonly during active treatment to manage common symptoms and side effects: pain, anxiety, insomnia, and nausea. However, most patients do not discuss cannabis use with their physicians. Instead, the internet and family/friends are the most common sources of cannabis information. Furthermore, most participants believe that cannabis products are safe and are unaware that the safety of many products is untested.
BACKGROUND: The goal of this study was to characterize cannabis use among patients with breast cancer, including their reasons for and timing of use, their sources of cannabis information and products, their satisfaction with the information found, their perceptions of its safety, and their dialogue about cannabis with their physicians. METHODS: United States-based members of the Breastcancer.org and Healthline.com communities with a self-reported diagnosis of breast cancer within 5 years (age ≥ 18 years) were invited to participate in an anonymous online survey. After informed consent was obtained, nonidentifiable data were collected and analyzed. RESULTS: Of all participants (n = 612), 42% (n = 257) reported using cannabis for relief of symptoms, which included pain (78%), insomnia (70%), anxiety (57%), stress (51%), and nausea/vomiting (46%). Furthermore, 49% of cannabis users believed that medical cannabis could be used to treat cancer itself. Of those taking cannabis, 79% had used it during treatment, which included systemic therapies, radiation, and surgery. At the same time, few (39%) had discussed it with any of their physicians. CONCLUSIONS: A significant percentage of survey participants (42%) used cannabis to address symptoms; approximately half of these participants believed that cannabis could treat cancer itself. Most participants used cannabis during active cancer treatment despite the potential for an adverse event during this vulnerable time. Furthermore, most participants believed that cannabis was safe and were unaware that product quality varied widely and depended on the source. This study reviews the research on medicinal cannabis in the setting of these findings to help physicians to recognize its risks and benefits for patients with cancer. LAY SUMMARY: Almost half of patients with breast cancer use cannabis, most commonly during active treatment to manage common symptoms and side effects: pain, anxiety, insomnia, and nausea. However, most patients do not discuss cannabis use with their physicians. Instead, the internet and family/friends are the most common sources of cannabis information. Furthermore, most participants believe that cannabis products are safe and are unaware that the safety of many products is untested.
Authors: Kirsten M King; Alyssa M Myers; Ariele J Soroka-Monzo; Ronald F Tuma; Ronald J Tallarida; Ellen A Walker; Sara Jane Ward Journal: Br J Pharmacol Date: 2017-07-27 Impact factor: 8.739
Authors: Jennifer E Layden; Isaac Ghinai; Ian Pray; Anne Kimball; Mark Layer; Mark W Tenforde; Livia Navon; Brooke Hoots; Phillip P Salvatore; Megan Elderbrook; Thomas Haupt; Jeffrey Kanne; Megan T Patel; Lori Saathoff-Huber; Brian A King; Josh G Schier; Christina A Mikosz; Jonathan Meiman Journal: N Engl J Med Date: 2019-09-06 Impact factor: 91.245
Authors: K Martell; A Fairchild; B LeGerrier; R Sinha; S Baker; H Liu; A Ghose; I A Olivotto; M Kerba Journal: Curr Oncol Date: 2018-06-28 Impact factor: 3.677
Authors: Ilana M Braun; Alexi Wright; John Peteet; Fremonta L Meyer; David P Yuppa; Dragana Bolcic-Jankovic; Jessica LeBlanc; Yuchiao Chang; Liyang Yu; Manan M Nayak; James A Tulsky; Joji Suzuki; Lida Nabati; Eric G Campbell Journal: J Clin Oncol Date: 2018-05-10 Impact factor: 44.544
Authors: Gil Bar-Sela; Idan Cohen; Salvatore Campisi-Pinto; Gil M Lewitus; Lanuel Oz-Ari; Ayellet Jehassi; Avivit Peer; Ilit Turgeman; Olga Vernicova; Paula Berman; Mira Wollner; Mor Moskovitz; David Meiri Journal: Cancers (Basel) Date: 2020-08-28 Impact factor: 6.575